GLPwatch
Mounjaro vs Wegovy
Drug comparison
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide by Eli Lilly) is a once-weekly injection approved for type 2 diabetes, while Wegovy (semaglutide by Novo Nordisk) is a once-weekly injection approved for obesity and reducing cardiovascular risk. Both are given under the skin, but they contain different active ingredients and are used for different health conditions.
AI summary of the sources below.
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | tirzepatide | semaglutide |
| Manufacturer | eli-lilly | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | obesity, cardiovascular risk reduction |
| Label updated | 2026-04-22 | 2026-05-05 |